关键信息
-
基因名
HHLA2
-
简介
HHLA2 protein, a key immune regulator, interacts with TMIGD2, providing crucial costimulation for T-cells during TCR-mediated activation. This interaction amplifies T-cell proliferation and cytokine production through an AKT-dependent signaling cascade, revealing HHLA2's role in enhancing T-cell responses and immune modulation. HHLA2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived HHLA2 protein, expressed by HEK293 , with C-His labeled tag. The total length of HHLA2 Protein, Cynomolgus (HEK293, His) is 325 a.a., with molecular weight of 60-70 kDa.
- 应用
-
别名
B7-H7; HHLA2; B7 Homolog 7
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
XP_005548285.1
-
表达区间
I21-N345
-
分子量
60-70 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
HHLA2 (Human High-Loading Immunoglobulin-like Protein 2) is a member of the B7 family of immune checkpoint molecules that has garnered significant attention in cancer research due to its role in modulating immune responses. Discovered as a novel co-stimulatory molecule, HHLA2 interacts with receptors on T cells, influencing their activation and function. Unlike its better-known counterparts such as PD-1 and CTLA-4, HHLA2's specific mechanisms and impacts on cancer progression are still being elucidated. Its expression is associated with various malignancies, where it may contribute to tumor immune evasion. The production of recombinant HHLA2 protein allows for in-depth studies of its structural characteristics, binding affinities, and functional interactions with T cell receptors. This research is vital for understanding how HHLA2 can be targeted for therapeutic purposes, particularly in the development of cancer immunotherapies. By examining the potential of HHLA2 as a biomarker for tumor progression and a target for immune modulation, researchers aim to create strategies that enhance anti-tumor immunity and improve patient outcomes.
